vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and UNITED SECURITY BANCSHARES (UBFO). Click either name above to swap in a different company.
CytomX Therapeutics, Inc. is the larger business by last-quarter revenue ($18.7M vs $13.5M, roughly 1.4× UNITED SECURITY BANCSHARES). UNITED SECURITY BANCSHARES runs the higher net margin — 25.2% vs -0.8%, a 26.0% gap on every dollar of revenue. On growth, UNITED SECURITY BANCSHARES posted the faster year-over-year revenue change (13.6% vs -25.7%). UNITED SECURITY BANCSHARES produced more free cash flow last quarter ($19.8M vs $-15.8M). Over the past eight quarters, UNITED SECURITY BANCSHARES's revenue compounded faster (3.0% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
United Security Bancshares is a bank holding company headquartered in Fresno, California. It operates 11 branches.
CTMX vs UBFO — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $13.5M |
| Net Profit | $-154.0K | $3.4M |
| Gross Margin | — | — |
| Operating Margin | -6.9% | 31.5% |
| Net Margin | -0.8% | 25.2% |
| Revenue YoY | -25.7% | 13.6% |
| Net Profit YoY | 97.6% | 36.8% |
| EPS (diluted) | — | $0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $13.5M | ||
| Q3 25 | — | $14.0M | ||
| Q2 25 | $18.7M | $12.6M | ||
| Q1 25 | $50.9M | $13.7M | ||
| Q4 24 | $38.1M | $11.9M | ||
| Q3 24 | $33.4M | $13.8M | ||
| Q2 24 | $25.1M | $13.0M | ||
| Q1 24 | $41.5M | $12.8M |
| Q4 25 | — | $3.4M | ||
| Q3 25 | — | $4.0M | ||
| Q2 25 | $-154.0K | $2.2M | ||
| Q1 25 | $23.5M | $2.7M | ||
| Q4 24 | $18.9M | $2.5M | ||
| Q3 24 | $5.7M | $3.8M | ||
| Q2 24 | $-6.5M | $4.3M | ||
| Q1 24 | $13.8M | $4.2M |
| Q4 25 | — | 31.5% | ||
| Q3 25 | — | 40.3% | ||
| Q2 25 | -6.9% | 24.0% | ||
| Q1 25 | 44.4% | 27.5% | ||
| Q4 24 | 46.4% | 27.5% | ||
| Q3 24 | 12.3% | 37.1% | ||
| Q2 24 | -33.7% | 46.4% | ||
| Q1 24 | 28.1% | 45.9% |
| Q4 25 | — | 25.2% | ||
| Q3 25 | — | 28.7% | ||
| Q2 25 | -0.8% | 17.2% | ||
| Q1 25 | 46.2% | 19.6% | ||
| Q4 24 | 49.6% | 20.9% | ||
| Q3 24 | 17.2% | 27.7% | ||
| Q2 24 | -26.0% | 33.0% | ||
| Q1 24 | 33.3% | 32.6% |
| Q4 25 | — | $0.18 | ||
| Q3 25 | — | $0.23 | ||
| Q2 25 | — | $0.13 | ||
| Q1 25 | — | $0.16 | ||
| Q4 24 | — | $0.14 | ||
| Q3 24 | — | $0.22 | ||
| Q2 24 | — | $0.25 | ||
| Q1 24 | — | $0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $264.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $139.7M |
| Total Assets | $175.1M | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $264.2M | ||
| Q3 25 | — | $211.1M | ||
| Q2 25 | $49.0M | $199.5M | ||
| Q1 25 | $47.6M | $198.4M | ||
| Q4 24 | $38.1M | $216.9M | ||
| Q3 24 | $40.6M | $216.8M | ||
| Q2 24 | $43.2M | $166.3M | ||
| Q1 24 | $36.2M | $168.6M |
| Q4 25 | — | $139.7M | ||
| Q3 25 | — | $137.4M | ||
| Q2 25 | $119.9M | $134.3M | ||
| Q1 25 | $25.0M | $132.9M | ||
| Q4 24 | $-456.0K | $130.4M | ||
| Q3 24 | $-23.5M | $132.9M | ||
| Q2 24 | $-31.2M | $127.3M | ||
| Q1 24 | $-31.7M | $124.2M |
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | $175.1M | $1.2B | ||
| Q1 25 | $98.5M | $1.2B | ||
| Q4 24 | $120.5M | $1.2B | ||
| Q3 24 | $139.0M | $1.3B | ||
| Q2 24 | $159.2M | $1.2B | ||
| Q1 24 | $184.7M | $1.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $22.1M |
| Free Cash FlowOCF − Capex | $-15.8M | $19.8M |
| FCF MarginFCF / Revenue | -84.6% | 146.0% |
| Capex IntensityCapex / Revenue | 0.1% | 16.8% |
| Cash ConversionOCF / Net Profit | — | 6.46× |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $36.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $22.1M | ||
| Q3 25 | — | $7.0M | ||
| Q2 25 | $-15.8M | $8.7M | ||
| Q1 25 | $-21.0M | $3.0M | ||
| Q4 24 | $-19.9M | $19.6M | ||
| Q3 24 | $-20.7M | $5.4M | ||
| Q2 24 | $-19.5M | $2.3M | ||
| Q1 24 | $-26.0M | $7.4M |
| Q4 25 | — | $19.8M | ||
| Q3 25 | — | $6.1M | ||
| Q2 25 | $-15.8M | $8.1M | ||
| Q1 25 | $-21.2M | $2.9M | ||
| Q4 24 | $-20.0M | $18.6M | ||
| Q3 24 | $-20.7M | $5.3M | ||
| Q2 24 | $-19.6M | $2.0M | ||
| Q1 24 | $-26.2M | $7.0M |
| Q4 25 | — | 146.0% | ||
| Q3 25 | — | 43.7% | ||
| Q2 25 | -84.6% | 64.3% | ||
| Q1 25 | -41.6% | 21.2% | ||
| Q4 24 | -52.5% | 156.0% | ||
| Q3 24 | -62.1% | 38.1% | ||
| Q2 24 | -78.2% | 15.5% | ||
| Q1 24 | -63.1% | 54.8% |
| Q4 25 | — | 16.8% | ||
| Q3 25 | — | 6.0% | ||
| Q2 25 | 0.1% | 4.6% | ||
| Q1 25 | 0.2% | 0.9% | ||
| Q4 24 | 0.2% | 8.7% | ||
| Q3 24 | 0.1% | 0.7% | ||
| Q2 24 | 0.4% | 2.2% | ||
| Q1 24 | 0.3% | 3.6% |
| Q4 25 | — | 6.46× | ||
| Q3 25 | — | 1.73× | ||
| Q2 25 | — | 4.01× | ||
| Q1 25 | -0.89× | 1.13× | ||
| Q4 24 | -1.05× | 7.87× | ||
| Q3 24 | -3.61× | 1.40× | ||
| Q2 24 | — | 0.54× | ||
| Q1 24 | -1.89× | 1.79× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
UBFO
Segment breakdown not available.
